4.6 Article

Transcriptome-Wide Prediction of miRNA Targets in Human and Mouse Using FASTH

期刊

PLOS ONE
卷 4, 期 5, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0005745

关键词

-

资金

  1. NIGMS NIH HHS [GM54250, R01 GM054250] Funding Source: Medline

向作者/读者索取更多资源

Transcriptional regulation by microRNAs (miRNAs) involves complementary base-pairing at target sites on mRNAs, yielding complex secondary structures. Here we introduce an efficient computational approach and software (FASTH) for genome-scale prediction of miRNA target sites based on minimizing the free energy of duplex structure. We apply our approach to identify miRNA target sites in the human and mouse transcriptomes. Our results show that short sequence motifs in the 59 end of miRNAs frequently match mRNAs perfectly, not only at validated target sites but additionally at many other, energetically favourable sites. High-quality matching regions are abundant and occur at similar frequencies in all mRNA regions, not only the 3'UTR. About one-third of potential miRNA target sites are reassigned to different mRNA regions, or gained or lost altogether, among different transcript isoforms from the same gene. Many potential miRNA target sites predicted in human are not found in mouse, and vice-versa, but among those that do occur in orthologous human and mouse mRNAs most are situated in corresponding mRNA regions, i.e. these sites are themselves orthologous. Using a luciferase assay in HEK293 cells, we validate four of six predicted miRNA-mRNA interactions, with the mRNA level reduced by an average of 73%. We demonstrate that a thermodynamically based computational approach to prediction of miRNA binding sites on mRNAs can be scaled to analyse complete mammalian transcriptome datasets. These results confirm and extend the scope of miRNA-mediated species-and transcript-specific regulation in different cell types, tissues and developmental conditions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Hematology

Methyl-CpG binding domain 4, DNA glycosylase (MBD4)-associated neoplasia syndrome associated with a homozygous missense variant in MBD4: Expansion of an emerging phenotype

Piers Blombery, Georgina L. Ryland, Lucy C. Fox, Zornitza Stark, Meg Wall, Anna Jarmolowicz, Ain Roesley, Ella R. Thompson, Sean M. Grimmond, Shyam Panicker, Fiona Kwok

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Genetics & Heredity

Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma

Jenette Creaney, Ann-Marie Patch, Venkateswar Addala, Sophie A. Sneddon, Katia Nones, Ian M. Dick, Y. C. Gary Lee, Felicity Newell, Ebony J. Rouse, Marjan M. Naeini, Olga Kondrashova, Vanessa Lakis, Apostolos Nakas, David Waller, Annabel Sharkey, Pamela Mukhopadhyay, Stephen H. Kazakoff, Lambros T. Koufariotis, Aimee L. Davidson, Priya Ramarao-Milne, Oliver Holmes, Qinying Xu, Conrad Leonard, Scott Wood, Sean M. Grimmond, Raphael Bueno, Dean A. Fennell, John Pearson, Bruce W. Robinson, Nicola Waddell

Summary: This study analyzed the genomic and immune features of malignant pleural mesothelioma (MPM) samples and identified driver genes, mutational signatures, and the tumor immune environment associated with MPM. The findings suggest that accounting for genomic and immune microenvironment status may influence future therapeutic planning.

GENOME MEDICINE (2022)

Letter Pathology

A rare diagnostically challenging case of CIC-DUX4 sarcoma arising in the neck

Stefanie Aranza, Christina Roydhouse, Catherine Mitchell, Joseph H. A. Vissers, Wing-Yee Lo, Sean M. Grimmond, Jane Kho

PATHOLOGY (2023)

Letter Pathology

Primary pancreatic spindle cell sarcoma with a TMEM106B::BRAF gene fusion treated with MEK inhibition

C. Mitchell, V. Malalasekera, A. J. Gill, J. H. A. Vissers, S. J. Luen, S. M. Grimmond, J. Lewin

PATHOLOGY (2023)

Letter Hematology

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Georgina L. Ryland, Masayuki Umeda, Linda Holmfeldt, Soren Lehmann, Morten Krogh Herlin, Jing Ma, Mahsa Khanlari, Jeffrey E. Rubnitz, Rhonda E. Ries, Hansen J. Kosasih, Paul G. Ekert, Hwee Ngee Goh, Ing S. Tiong, Sean M. Grimmond, Claudia Haferlach, Ryan B. Day, Timothy J. Ley, Soheil Meshinchi, Xiaotu Ma, Piers Blombery, Jeffery M. Klco

Article Multidisciplinary Sciences

Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment

Magnus Zethoven, Luciano Martelotto, Andrew Pattison, Blake Bowen, Shiva Balachander, Aidan Flynn, Fernando J. Rossello, Annette Hogg, Julie A. Miller, Zdenek Frysak, Sean Grimmond, Lauren Fishbein, Arthur S. Tischler, Anthony J. Gill, Rodney J. Hicks, Patricia L. M. Dahia, Roderick Clifton-Bligh, Karel Pacak, Richard W. Tothill

Summary: This study characterizes the molecular subtypes and gene expression patterns associated with metastasis in pheochromocytomas and paragangliomas using single-nuclei and bulk-tissue RNA-seq techniques.

NATURE COMMUNICATIONS (2022)

Correction Multidisciplinary Sciences

The repertoire of mutational signatures in human cancer (vol 578, pg 94, 2020)

Ludmil B. Alexandrov, Jaegil Kim, Nicholas J. Haradhvala, Mi Ni Huang, Alvin Wei Tian Ng, Yang Wu, Arnoud Boot, Kyle R. Covington, Dmitry A. Gordenin, Erik N. Bergstrom, S. M. Ashiqul Islam, Nuria Lopez-Bigas, Leszek J. Klimczak, John R. McPherson, Sandro Morganella, Radhakrishnan Sabarinathan, David A. Wheeler, Ville Mustonen, Gad Getz, Steven G. Rozen, Michael R. Stratton

NATURE (2023)

Correction Multidisciplinary Sciences

Patterns of somatic structural variation in human cancer genomes (vol 578, pg 112, 2020)

Yilong Li, Nicola D. Roberts, Jeremiah A. Wala, Ofer Shapira, Steven E. Schumacher, Kiran Kumar, Ekta Khurana, Sebastian Waszak, Jan O. Korbel, James E. Haber, Marcin Imielinski, Joachim Weischenfeldt, Rameen Beroukhim, Peter J. Campbell

NATURE (2023)

Correction Multidisciplinary Sciences

The evolutionary history of 2,658 cancers (vol 578, pg 122, 2020)

Moritz Gerstung, Clemency Jolly, Ignaty Leshchiner, Stefan C. Dentro, Santiago Gonzalez, Daniel Rosebrock, Thomas J. Mitchell, Yulia Rubanova, Pavana Anur, Kaixian Yu, Maxime Tarabichi, Amit Deshwar, Jeff Wintersinger, Kortine Kleinheinz, Ignacio Vazquez-Garcia, Kerstin Haase, Lara Jerman, Subhajit Sengupta, Geoff Macintyre, Salem Malikic, Nilgun Donmez, Dimitri G. Livitz, Marek Cmero, Jonas Demeulemeester, Steven Schumacher, Yu Fan, Xiaotong Yao, Juhee Lee, Matthias Schlesner, Paul C. Boutros, David D. Bowtell, Hongtu Zhu, Gad Getz, Marcin Imielinski, Rameen Beroukhim, S. Cenk Sahinalp, Yuan Ji, Martin Peifer, Florian Markowetz, Ville Mustonen, Ke Yuan, Wenyi Wang, Quaid D. Morris, Paul T. Spellman, David C. Wedge, Peter Van Loo

NATURE (2023)

Correction Multidisciplinary Sciences

Analyses of non-coding somatic drivers in 2,658 cancer whole genomes (vol 578, pg 102, 2020)

Esther Rheinbay, Morten Muhlig Nielsen, Federico Abascal, Jeremiah A. Wala, Ofer Shapira, Grace Tiao, Henrik Hornshoj, Julian M. Hess, Randi Istrup Juul, Ziao Lin, Lars Feuerbach, Radhakrishnan Sabarinathan, Tobias Madsen, Jaegil Kim, Loris Mularoni, Shimin Shuai, Andres Lanzos, Carl Herrmann, Yosef E. Maruvka, Ciyue Shen, Samirkumar B. Amin, Pratiti Bandopadhayay, Johanna Bertl, Keith A. Boroevich, John Busanovich, Joana Carlevaro-Fita, Dimple Chakravarty, Calvin Wing Yiu Chan, David Craft, Priyanka Dhingra, Klev Diamanti, Nuno A. Fonseca, Abel Gonzalez-Perez, Qianyun Guo, Mark P. Hamilton, Nicholas J. Haradhvala, Chen Hong, Keren Isaev, Todd A. Johnson, Malene Juul, Andre Kahles, Abdullah Kahraman, Youngwook Kim, Jan Komorowski, Kiran Kumar, Sushant Kumar, Donghoon Lee, Kjong-Van Lehmann, Yilong Li, Eric Minwei Liu, Lucas Lochovsky, Keunchil Park, Oriol Pich, Nicola D. Roberts, Gordon Saksena, Steven E. Schumacher, Nikos Sidiropoulos, Lina Sieverling, Nasa Sinnott-Armstrong, Chip Stewart, David Tamborero, Jose M. C. Tubio, Husen M. Umer, Liis Uuskuela-Reimand, Claes Wadelius, Lina Wadi, Xiaotong Yao, Cheng-Zhong Zhang, Jing Zhang, James E. Haber, Asger Hobolth, Marcin Imielinski, Manolis Kellis, Michael S. Lawrence, Christian von Mering, Hidewaki Nakagawa, Benjamin J. Raphael, Mark A. Rubin, Chris Sander, Lincoln D. Stein, Joshua M. Stuart, Tatsuhiko Tsunoda, David A. Wheeler, Rory Johnson, Jueri Reimand, Mark Gerstein, Ekta Khurana, Peter J. Campbell, Nuria Lopez-Bigas, Joachim Weischenfeldt, Rameen Beroukhim, Inigo Martincorena, Jakob Skou Pedersen, Gad Getz

NATURE (2023)

Article Genetics & Heredity

Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare

Zornitza Stark, Tiffany Boughtwood, Matilda Haas, Jeffrey Braithwaite, Clara L. Gaff, Ilias Goranitis, Amanda B. Spurdle, David P. Hansen, Oliver Hofmann, Nigel Laing, Sylvia Metcalfe, Ainsley J. Newson, Hamish S. Scott, Natalie Thorne, Robyn L. Ward, Marcel E. Dinger, Stephanie Best, Janet C. Long, Sean M. Grimmond, John Pearson, Nicola Waddell, Christopher P. Barnett, Matthew Cook, Michael Field, David Fielding, Stephen B. Fox, Jozef Gecz, Adam Jaffe, Richard J. Leventer, Paul J. Lockhart, Sebastian Lunke, Andrew J. Mallett, Julie McGaughran, Linda Mileshkin, Katia Nones, Tony Roscioli, Ingrid E. Scheffer, Christopher Semsarian, Cas Simons, David M. Thomas, David R. Thorburn, Richard Tothill, Deborah White, Sally Dunwoodie, Peter T. Simpson, Peta Phillips, Marie-Jo Brion, Keri Finlay, Michael CJ. Quinn, Tessa Mattiske, Emma Tudini, Kirsten Boggs, Sean Murray, Kathy Wells, John Cannings, Andrew H. Sinclair, John Christodoulou, Kathryn N. North

Summary: Australian Genomics is a national collaborative partnership that aims to integrate genomics into healthcare through a whole-of-system approach. It has evaluated genomic testing outcomes in over 5,200 individuals across rare disease and cancer studies and provided evidence-based changes in policy and practice, resulting in government funding and access to genomic tests. It has also developed national skills, infrastructure, policy, and data resources to support data sharing and improve clinical genomic delivery.

AMERICAN JOURNAL OF HUMAN GENETICS (2023)

Article Biochemistry & Molecular Biology

S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer

Ronnie Ren Jie Low, Ka Yee Fung, Hugh Gao, Adele Preaudet, Laura F. Dagley, Jumana Yousef, Belinda Lee, Samantha J. Emery-Corbin, Rune H. Larsen, Nadia J. Kershaw, Antony W. Burgess, Peter Gibbs, Frederic Hollande, Michael D. W. Griffin, Sean M. Grimmond, Tracy L. Putoczki

Summary: Epithelial-mesenchymal transition (EMT) is a continuum associated with cancer progression, invasive capabilities, and metastasis. Through a sporadic model of pancreatic cancer, a murine organoid biobank was generated to study the different EMT states. It was found that organoid morphology predicts the EMT state, and that TGF beta 1 induces changes in the S100 family, complete EMT, and high-grade tumors. S100A4 may serve as a biomarker for predicting EMT state, disease progression, and outcome in pancreatic cancer patients.

CELL DEATH AND DIFFERENTIATION (2023)

Article Oncology

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Genevieve Dall, Cassandra J. J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake, Wenying Zhu, Joseph H. A. Vissers, Justin Bedo, Jocelyn Penington, Matthew J. J. Wakefield, Damien Kee, Amandine Carmagnac, Ratana Lim, Kristy Shield-Artin, Briony Milesi, Amanda Lobley, Elizabeth L. L. Kyran, Emily O'Grady, Joshua Tram, Warren Zhou, Devindee Nugawela, Kym Pham Stewart, Reece Caldwell, Lia Papadopoulos, Ashley P. P. Ng, Alexander Dobrovic, Stephen B. B. Fox, Orla McNally, Jeremy D. D. Power, Tarek Meniawy, Teng Han Tan, Ian M. M. Collins, Oliver Klein, Stephen Barnett, Inger Olesen, Anne Hamilton, Oliver Hofmann, Sean Grimmond, Anthony T. T. Papenfuss, Clare L. L. Scott, Holly E. E. Barker

Summary: This study identified mutations in DNA repair genes in a subset of uterine leiomyosarcoma patients and found that these patients may benefit from PARP inhibitor therapy. Patient-derived xenograft models confirmed the efficacy of this treatment approach.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Oncology

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer

Jessica L. Chitty, Michelle Yam, Lara Perryman, Amelia L. Parker, Joanna N. Skhinas, Yordanos F. I. Setargew, Ellie T. Y. Mok, Emmi Tran, Rhiannon D. Grant, Sharissa L. Latham, Brooke A. Pereira, Shona C. Ritchie, Kendelle J. Murphy, Michael Trpceski, Alison D. Findlay, Pauline Melenec, Elysse C. Filipe, Audrey Nadalini, Sipiththa Velayuthar, Gretel Major, Kaitlin Wyllie, Michael Papanicolaou, Shivanjali Ratnaseelan, Phoebe A. Phillips, George Sharbeen, Janet Youkhana, Alice Russo, Antonia Blackwell, Jordan F. Hastings, Morghan C. Lucas, Cecilia R. Chambers, Daniel A. Reed, Janett Stoehr, Claire Vennin, Ruth Pidsley, Anaiis Zaratzian, Andrew M. Da Silva, Michael Tayao, Brett Charlton, David Herrmann, Max Nobis, Susan J. Clark, Andrew V. Biankin, Amber L. Johns, David R. Croucher, Adnan Nagrial, Anthony J. Gill, Sean M. Grimmond, Marina Pajic, Paul Timpson, Wolfgang Jarolimek, Thomas R. Cox

Summary: By inhibiting the activity of pan-lysyl oxidase, PXS-5505 can reduce fibrosis and stiffness in pancreatic tumors, decrease cancer cell invasion and metastasis, and enhance the efficacy of chemotherapy.

NATURE CANCER (2023)

Review Oncology

Diagnosing primary pancreatic acinar cell carcinoma-Clinical correlation of radiological/molecular imaging, histopathologic features and whole genome/transcriptome profiling, and review of the literature

Kevin Tran, Owen W. J. Prall, Catherine Mitchell, Angela Chou, Anthony J. Gill, Sean M. Grimmond, Grace Kong, Gareth Kiernan, Cristina Torche, Lara Lipton, Benjamin Thomson, H. S. Ko

Summary: Pancreatic acinar cell carcinoma (ACC) is a rare pancreatic neoplasm that is often difficult to diagnose due to lack of awareness and knowledge about its clinical, radiological, and pathological characteristics. Accurate diagnosis is crucial as it can be easily mistaken for pancreatic ductal adenocarcinoma (PDAC) or pancreatic neuroendocrine tumor (PNET). This case study highlights the importance of integrating clinical, imaging, molecular histopathological, and genomic analysis for the diagnosis and treatment of complex pancreatic ACC.

CURRENT PROBLEMS IN CANCER: CASE REPORTS (2023)

暂无数据